Vosoritide is a recombinant peptide-based active pharmaceutical ingredient (API) belonging to the class of C-type natriuretic peptide (CNP) analogues. It is a modified human CNP analogue developed for the treatment of achondroplasia, a genetic disorder that affects bone growth. Vosoritide is marketed as VOXZOGO and is administered by subcutaneous injection. The FDA approved vosoritide in 2021, and the European Medicines Agency has authorised Voxzogo for achondroplasia in patients with open growth plates.
Vosoritide is a 39-amino-acid peptide containing the 37 C-terminal amino acids of human CNP53 together with Pro-Gly at the N-terminus. The Pro-Gly extension provides resistance to degradation by neutral endopeptidase (NEP). Its two cysteine residues form an intramolecular disulfide bond that is important for its biological activity.
Vosoritide has the molecular formula C176H290N56O51S3 and a molecular weight of approximately 4.1 kDa. PubChem identifies the compound with CAS Number 1480724-61-5, while FDA's Substance Registration System identifies the substance under UNII 7SE5582Q2P. The development code for vosoritide is BMN-111.
Vosoritide is a recombinant peptide manufactured using Escherichia coli through recombinant DNA technology. The active peptide contains a cyclic disulfide structure formed between Cys23 and Cys39. This structural feature is essential for the biological activity of the peptide.
Vosoritide is a C-type natriuretic peptide analogue that acts primarily through natriuretic peptide receptor-B (NPR-B). Binding to NPR-B increases intracellular cyclic guanosine monophosphate (cGMP), which counteracts excessive signaling associated with the FGFR3 pathway in achondroplasia. This promotes chondrocyte proliferation and differentiation and supports longitudinal bone growth.
The pharmacological action of vosoritide is therefore different from conventional small-molecule medicines because it is a recombinant peptide designed to reproduce and extend selected biological activity of endogenous CNP.
Vosoritide API is relevant to biotechnology and pharmaceutical manufacturers developing peptide-based medicines for skeletal growth disorders. As a Vosoritide API manufacturer and supplier in India, the product can be positioned for pharmaceutical development, analytical research and manufacturing applications involving recombinant peptide APIs.
EMA's assessment describes an extensive analytical control strategy for vosoritide active substance. The active-substance specification includes peptide identity testing, appearance, bacterial endotoxins, bioburden, purity and multimer content, deamidation, related substances, host-cell proteins, active fraction, peptide concentration, pH, osmolality and polysorbate 80.
Because Vosoritide is a recombinant peptide rather than a conventional synthetic small molecule, its quality-control strategy should emphasize peptide identity, purity, biological activity, aggregation/multimer formation and process-related impurities.
Vosoritide is used for the treatment of achondroplasia, a genetic skeletal disorder associated with impaired bone growth. FDA records show marketing approvals for Voxzogo for pediatric patients with achondroplasia and open epiphyses, including the expanded indication for patients younger than 5 years.
The European Medicines Agency currently lists Voxzogo for treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed, with diagnosis confirmed by appropriate genetic testing.
Vosoritide can therefore be categorized as a recombinant peptide API, CNP analogue, NPR-B agonist, skeletal growth disorder API and achondroplasia pharmaceutical ingredient.
Vosoritide is a 39-amino-acid recombinant peptide with a molecular weight of approximately 4.1 kDa. Its two cysteine residues form an intramolecular disulfide bond, producing the cyclic portion of the peptide that contributes to biological activity.
The FDA describes vosoritide drug product as a sterile, preservative-free white-to-yellow lyophilized powder for subcutaneous administration after reconstitution. The marketed product is supplied in 0.4 mg, 0.56 mg and 1.2 mg vial strengths.
Japanese product information describes the lyophilized product as a white-to-light-yellow powder with a pH of 5.0–6.0 and an osmolality ratio of 0.8–1.1 relative to physiological saline. These values describe the pharmaceutical product rather than a universal bulk API specification.
Quality control of Vosoritide API requires analytical procedures suitable for recombinant peptides. EMA reports that peptide mapping, tryptic digestion and RP-HPLC are used for identity, while SEC, SCX and RP-HPLC are used to evaluate different aspects of purity and related substances. Biological activity is also assessed using a cell-based assay.
Important quality attributes include peptide concentration, active peptide fraction, aggregates or multimers, deamidated species, host-cell proteins, bioburden and bacterial endotoxins. These controls are particularly important for recombinant peptide APIs manufactured using microbial expression systems.
Because Vosoritide is a biological peptide, conventional small-molecule API parameters such as melting point, residue on ignition and specific rotation are not appropriate primary quality attributes for the bulk active substance. The release specification should instead be based on validated peptide and biological assays.
Vosoritide was developed as BMN-111, a modified recombinant human CNP analogue. The peptide was designed to retain activity at NPR-B while increasing resistance to NEP-mediated degradation compared with endogenous CNP.
The EMA assessment confirmed the primary structure and expected molecular weight of vosoritide and verified the correct intramolecular disulfide bond. Extensive characterization was conducted to evaluate product-related impurities and degradation pathways.
Vosoritide can therefore be categorized as a recombinant peptide API, CNP analogue API, NPR-B agonist API, biotechnology-derived pharmaceutical ingredient and achondroplasia API.
Vosoritide is manufactured using recombinant DNA technology in E. coli. The resulting peptide undergoes purification and processing to produce the active substance used in the pharmaceutical product.
VOXZOGO is supplied as a sterile lyophilized powder for reconstitution. FDA documentation lists vial strengths of 0.4 mg, 0.56 mg and 1.2 mg. After reconstitution, the product is administered subcutaneously.
The formulation contains excipients including trehalose dihydrate, mannitol, sodium citrate dihydrate, methionine, citric acid monohydrate and polysorbate 80. Sterile water for injection is supplied as the diluent.
Vosoritide drug product should be stored according to the applicable approved product information and validated stability data. Swissmedic reports storage of the lyophilized Voxzogo product at 2°C to 8°C, with stability data supporting a 36-month shelf life for the evaluated product.
Bulk vosoritide API should be handled according to its specific approved storage conditions, stability data and quality specification. Appropriate controls should protect the recombinant peptide from conditions that could affect its structure, biological activity, aggregation state or chemical purity.
Vosoritide is a specialized recombinant peptide API developed for a rare skeletal growth disorder. Its mechanism through NPR-B and cGMP signaling provides a targeted approach to the abnormal growth-plate signaling associated with achondroplasia.
For pharmaceutical manufacturers and developers, quality control should focus on peptide identity, purity, active fraction, biological potency, aggregation/multimer content, host-cell proteins, endotoxins, bioburden, concentration and physicochemical properties. EMA specifically confirms these attributes within the vosoritide active-substance control strategy.
As a specialized biotechnology-derived ingredient, Vosoritide can be positioned for applications involving achondroplasia medicines, recombinant peptide therapeutics, skeletal growth disorder research and pharmaceutical biotechnology.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| pH (1% Solution) | 5.0–6.0 |
| Water Content | NMT 0.5% |